Latest Breaking News On - Timothy warbington - Page 2 : comparemela.com

Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain

20.12.2023 - PHOENIX, AZ / ACCESSWIRE / December 20, 2023 / Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ), a biotechnology company has received clearance from the FDA to conduct a phase 1/2 clinical trial using their innovative StemSpine treatment .

Creative Medical Technology Holdings (NASDAQ: CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem™ For Addressing Chronic Lower Back Pain - Creative Medical Tech (NASDAQ:CELZ)

Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a biotechnology company has received clearance from the FDA to conduct a phase 1/2 clinical trial using their innovative StemSpine® treatment known as AlloStem™.

Creative Medical Technology Reports IRB Approval for Phase ½ Clinical Trial of Novel Cell Therapy to Treat Type 1 Diabetes

Creative Medical Technology Holdings Provides Corporate Update

Continuing to Advance Regenerative Therapies for Diabetes and Chronic Lower Back Pain Strong Financial Position with No Long-Term Debt  PHOENIX, Nov. 15, 2023 /PRNewswire/ Creative Medical.

Creative Medical Technology Reports IRB Approval for Phase ½ Clinical Trial of Novel Cell Therapy to Treat Type 1 Diabetes